ClinicalTrials.gg
CompletedNCT06798454Updated Nov 24, 2025

Single Ascending Dose Study to Evaluate Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT201 in Healthy Subjects and Patients (PBC/PSC)

A Phase 1 interventional study of PVT201 and Placebo in Primary Biliary Cholangitis (PBC), sponsored by Parvus Therapeutics, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Parvus Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Liver Cirrhosis, Biliary with a site in Australia — 2 open to participants now, 4 under way, 3 of them phase 3. Liver Cirrhosis, Biliary · Australia.

Enrollment
15th of 17
24 · median 76
Started
2024
with 2 others
Phase 1
Only one
of the 18
Registered
18th of 18
by date
Lead sponsor
1 of 18
Parvus Therapeutics, Inc.

Among the 18 studies in Liver Cirrhosis, Biliary with a site in Australia, this one is the 15th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2024, is the only one in phase 1, and was the 18th registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

2 of the 18 studies in Liver Cirrhosis, Biliary with a site in Australia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Liver Cirrhosis, Biliary with a site in Australia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn what happens to PVT201 when it enters your body and how it affects your immune system. It will also learn about the safety of PVT201 after a single dose. The main questions it aims to answer are:

Will participants experience any side effects when taking PVT201? How long does it take PVT201 to leave your body after you take it?

Healthy volunteers will:

stay in the clinic for two nights, get one dose of PVT201 or a placebo intravenously (through a vein) on Day 1, have blood drawn periodically throughout their stay and be monitored for side effects, and return to the clinic approximately one week after their dose for a final study visit.

Patients with primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC) will have the same procedures performed as healthy volunteers; however, none of the patients will receive placebo (all patients will be given PVT201).

Read the detailed description

This is a randomized, double-blind, placebo-controlled, single ascending dose, multi-cohort study conducted in healthy participants and patients with PBC/PSC.

Healthy adult participants will be enrolled to 1 of 4 main cohorts (Cohorts 1-4; 6 participants per cohort), and randomized to receive single ascending doses of PVT201 or placebo.

Dosing in each cohort begins with two sentinel subjects randomized such that one will receive PVT201 and the other will receive placebo (normal saline; 0.9% sodium chloride). The safety and tolerability of each sentinel participant will be monitored in the clinic until 24 hours post-dose. Following completion of Day 2 assessments for sentinel participants, all available safety/tolerability information will be reviewed prior to making the decision to dose the remaining participants in each cohort. Participants will be discharged after Day 2 assessments have been completed, and will return to the clinic for a final study visit on Day 7.

After the completion of each cohort, the decision to advance to the next dose cohort will be made by the Safety Review Committee (SRC) following review of safety and tolerability data of at least 4 of 6 participants, up to and including the Day 7 visit.

Cohorts will be dosed in an escalating order, unless otherwise indicated by the Safety Review Committee. At the discretion of the Sponsor and Safety Review Committee, healthy adult participants may be enrolled in up to one additional cohorts (6 participants per cohort) and randomized to receive single doses of PVT201 or placebo (ratio 2:1 active:placebo), to achieve the objectives of the study. If an additional cohort is required, it will commence with two sentinels, with one of the two sentinels randomized to receive PVT201 and the other randomized to receive placebo.

After completion of a minimum of 4 cohorts and with the approval of the SRC, the final cohort of the study will enroll up to 6 patients diagnosed with either PBC or PSC (of which at least half of the participants must have PBC). This cohort will not be blinded or placebo controlled, but will commence with one sentinel subject that will be monitored as noted above for previous cohorts prior to subsequent subject dosing. The dose level of the cohort will be the highest dose administered in the previous cohorts that was deemed safe and well tolerated by the SRC. All study visits and procedures noted for the healthy volunteer cohorts will also apply to the PBC/PSC patient cohort.

03

Conditions studied

  • Primary Biliary Cholangitis (PBC)

Keywords

  • first-in-human
  • healthy volunteer
  • single ascending dose
  • PBC
  • PSC
  • randomized
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

HEALTHY VOLUNTEER ELIGIBILITY CRITERIA

Inclusion Criteria:

  1. Healthy male or female, aged between 18 and 65 years, inclusive at Screening.
  2. (BMI) of 18.0 to 32.0 kg/m2, inclusive, with body weight ≥ 50.0 kg and \< 120.0 kg.
  3. Carry the HLA DRB4*0101 or DRB4*0103 allele.
  4. Participant is medically healthy (in the opinion of the Investigator), as determined by pre-study medical history and without CS abnormalities.
  5. Female participants must be of non-, or, if of child-bearing potential:

    1. Must have a negative serum pregnancy test at the Screening visit and a negative urine pregnancy test on Day -1.
    2. Must agree not to donate ova or attempt to become pregnant from the time of signing consent until at least 30 days after the dose of study drug.
    3. If not exclusively in a same-sex relationship or abstinent as a committed lifestyle, must agree to use adequate established at Screening until at least 30 days after the dose of study drug.
  6. Male participants must:

    1. Agree not to donate sperm from the time of signing consent until at least 90 days after the dose of study drug.
    2. If engaging in sexual intercourse with a female partner who could become pregnant, must agree to use adequate contraception from the time of signing consent until at least 90 days after the dose of study drug.

Exclusion Criteria:

  1. Any active infection that requires systemically absorbed antibiotic, antifungal, antiparasitic or antiviral medications.
  2. History of reaction, anaphylaxis or other CS reactions or known allergy to the study drug or its ingredients including but not limited to dextran.
  3. History of any disorder which, in the opinion of the Investigator would make implementation of the protocol or interpretation of study results difficult, or that would put the participant at risk by participating in the study.
  4. Participant has undergone splenectomy or thymectomy.
  5. Laboratory results at Screening that indicate inadequate renal function, with estimated of \< 60 mL/min/1.73m2.
  6. Liver function test results elevated more than 1.5-fold above the for GGT, ALP, or ALT.
  7. Total > 1.5-fold above the upper limit of normal.
  8. Use of any prescription medication within 14 days prior to the dose of study drug and/or over-the-counter medication/vitamins/supplements/herbal/plant-derived medications within 7 days prior to the dose of study drug.
  9. Concurrent enrollment in another clinical study, or participation in another clinical study within 30 days prior to Screening.
  10. Positive alcohol breath test at Screening, upon admission to the clinic on Day -1.
  11. Positive urine drugs of abuse test at Screening, upon admission to the clinic on Day -1.
  12. Participant has a positive cotinine test upon admission to the clinic on Day -1.
  13. Participant is breastfeeding/lactating or pregnant, or planning to breastfeed or become pregnant during the study.
  14. Positive surface antigen (HBsAg), (HepC) virus antibody, or human immunodeficiency () antibody tests.
  15. Known substance abuse or medical, psychological, or social conditions that in the opinion of the study doctor would make the participant unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.

PBC/PSC PATIENT ELIGIBILITY CRITERIA

Inclusion Criteria:

  1. Male or female, aged between 18 and 75 years, inclusive at Screening.
  2. Body mass index (BMI) of 18.0 to 35.0 kg/m2, inclusive, with body weight ≥ 50.0 kg and \< 120.0 kg.
  3. Carry the HLA DRB4*0101 or DRB4*0103 allele.
  4. Participant is medically healthy (in the opinion of the Investigator), as determined by pre-study medical history and without CS abnormalities.
  5. Male or female with a diagnosis of primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC).
  6. For subjects on any medication used to treat the symptoms of PBC or PSC (examples: UDCA, OCA, seladelpar), subjects must be on a stable dose for a minimum of 2 months prior to Day 1 and expected to stay on treatment for duration of study participation OR must have been off treatment for at least 2 months prior to Day 1.
  7. Subjects with inflammatory bowel disease (IBD) must have been on stable therapy > 2 months prior to Day 1.
  8. Female participants must be of non-child-bearing potential, or, if of child-bearing potential:

    1. Must have a negative serum pregnancy test at the Screening visit and a negative urine pregnancy test on Day -1,
    2. Must agree not to donate ova or attempt to become pregnant from the time of signing consent until at least 30 days after the dose of study drug,
    3. If not exclusively in a same-sex relationship or abstinent as a committed lifestyle, must agree to use adequate contraception established at Screening until at least 30 days after the dose of study drug.
  9. Male participants must:

    1. Agree not to donate sperm from the time of signing consent until at least 90 days after the dose of study drug,
    2. If engaging in sexual intercourse with a female partner who could become pregnant, must agree to use adequate contraception from the time of signing consent until at least 90 days after the dose of study drug.

Exclusion Criteria:

  1. Current or a history of hepatic decompensation events.
  2. Subject is diagnosed with Gilbert's Syndrome.
  3. Subjects who have previously undergone liver transplantation.
  4. History of ileectomy, colostomy, colectomy, splenectomy, or thymectomy.
  5. Any active infection that requires systemically absorbed antibiotic, antifungal, antiparasitic or antiviral medications.
  6. Co-existing liver or biliary diseases, such as choledocholithiasis, acute or chronic hepatitis, hepatitis, alcoholic liver disease, acute infection of bile duct system or gall bladder, history of gastrointestinal bleeding (secondary to portal hypertension), hepatorenal syndrome, cholangiocarcinoma diagnosed or suspected liver cancers.
  7. Presence of conditions that may cause non-hepatogenic ALP elevations (eg, Paget's disease) or conditions that may lead to a of less than 2 years.
  8. History of active within the past year except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated.
  9. Positive Hepatitis B surface antigen (HBsAg), Hepatitis C (HepC) virus antibody, or human immunodeficiency (HIV) antibody tests.
  10. Laboratory Screening Results:

    1. AST >5 x ULN,
    2. ALT >5 x ULN,
    3. ALP > 10 x ULN,
    4. Total bilirubin > 1.5 x ULN,
    5. Albumin \< 35 g/L,
    6. Total white blood cells (WBC) \<3000 cells/mm3,
    7. (ANC) \<1500 cells/mm3,
    8. count \<130,000/mm3, unless on stable anticoagulants at the discretion of the investigator,
    9. (international normalized ratio, INR) >1.3,
    10. Serum creatinine >175 µmol/L or creatinine clearance \<50 mL/min.
  11. History of hypersensitivity reaction, anaphylaxis or other CS reactions or known allergy to the study drug or its ingredients including but not limited to dextran.
  12. Positive alcohol breath test at Screening, upon admission to the clinic on Day -1.
  13. Positive urine drugs of abuse test at Screening, upon admission to the clinic on Day -1.
  14. Participant has a positive cotinine test at Screening, upon admission to the clinic on Day -1.
  15. Participant is breastfeeding/lactating or pregnant, or planning to breastfeed or become pregnant during the study.
  16. therapies including methotrexate, azathioprine, or long-tern systemic within 2 months prior to Day 1.
  17. Treatment with any other therapy or device within 6 weeks or within 5 half-lives, whichever is longer, prior to Day 1.
  18. Known substance abuse or medical, psychological, or social conditions other than PBC or PSC, or prior therapy that in the opinion of the PI would make the participant unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    PVT201

    PVT201 will be administered as a single IV dose. Planned doses are: Cohort 1 Healthy Volunteers: A mg/kg Cohort 2 Healthy Volunteers: B mg/kg Cohort 3 Healthy Volunteers: C mg/kg Cohort 4 Healthy Volunteers: D mg/kg Final Cohort PBC/PSC Patients: the highest dose that was deemed safe and well tolerated in the Healthy Volunteer cohorts

    Drug: PVT201

  • Placebo comparator
    Placebo (normal saline, 0.9% sodium chloride)

    All Healthy Volunteer cohorts will be administered either PVT201 or placebo in a ratio of 2:1 PVT201:placebo. Patient receiving placebo will be administered an equivalent volume of normal saline as a single IV dose. The PBC/PSC patients in the final cohort will not be administered placebo - all patients in this cohort will receive PVT201.

    Other: Placebo

Interventions

  • DrugPVT201

    Navacims are a novel class of nano-particle-based therapeutics being developed for the treatment of autoimmune diseases. A navacim consists of an iron oxide core surrounded by dextran that has been linked to multiple copies of a major histocompatibility complex Class II molecule and peptide. The peptide representing a disease-associated autoantigen and its paired MHC II molecule are specific to each autoimmune disease, and will be recognized by the T-cell antigen receptor. PVT201 is a navacim that will be used to target human PDC-reactive effector T-cells in patients with primary biliary cholangitis (PBC), converting them to Type 1 regulatory cells. IV delivery of navacims in nonclinical models of PBC induced immune tolerance and attenuation of disease pathology without impairing normal immunity to vaccines or viral and bacterial infections. PVT201 will be administered intravenously.

    Also known as: Navacim

  • OtherPlacebo

    Participants randomized to placebo will be administered normal saline IV.

    Also known as: normal saline, 0.9% NaCl

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.

    Safety endpoints include incidence, severity, and relationship of adverse events (AEs) and serious adverse events (SAEs) (including withdrawals due to AEs);

    Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)

  2. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.

    Safety endpoints include change from baseline in vital signs (temperature measured in degrees Celsius)

    Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)

  3. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.

    Safety endpoints include change from baseline in vital signs (heart rate measured in beats per minute)

    Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)

  4. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.

    Safety endpoints include change from baseline in vital signs (blood pressure measured in mmHg)

    Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)

  5. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.

    Safety endpoints include change from baseline in clinical laboratory parameters (hematology)

    Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)

  6. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.

    Safety endpoints include change from baseline in clinical laboratory parameters (serum chemistry including liver function tests).

    Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)

  7. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.

    Safety endpoints include change from baseline in clinical laboratory parameters (coagulation parameters).

    Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)

  8. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.

    Safety endpoints include change from baseline in clinical laboratory parameters (urinalysis).

    Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)

  9. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.

    Safety endpoints include change from baseline in electrocardiogram (ECG) parameters: PR Interval (msec)

    Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)

  10. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.

    Safety endpoints include change from baseline in electrocardiogram (ECG) parameters: QRS Duration (msec)

    Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)

  11. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.

    Safety endpoints include change from baseline in electrocardiogram (ECG) parameters: QT Interval (msec)

    Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)

  12. To evaluate the safety and tolerability of a single IV dose of PVT201 in healthy participants and in PBC/PSC patients.

    Safety endpoints include change from baseline in electrocardiogram (ECG) parameters: QTcF (msec)

    Time frame: To be measured at Baseline, Day 1, Day 2, and Day 7 (~7 days)

Secondary outcomes

  1. To measure the pharmacokinetics (PK) of PVT201 in plasma following a single IV dose in healthy participants and in PBC/PSC patients.

    Pharmacokinetic parameters to be evaluated include area under the concentration-time curve from 0 to time of last quantifiable concentration (AUClast).

    Time frame: Day 1: pre-dose and t= 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr; Day 2 = 24 hr; Day 7

  2. To measure the pharmacokinetics (PK) of PVT201 in plasma following a single IV dose in healthy participants and in PBC/PSC patients.

    Pharmacokinetic parameters to be evaluated include maximum concentrations (Cmax).

    Time frame: Day 1: pre-dose and t= 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr; Day 2 = 24 hr; Day 7

  3. To measure the pharmacokinetics (PK) of PVT201 in plasma following a single IV dose in healthy participants and in PBC/PSC patients.

    Pharmacokinetic parameters to be evaluated include time at which the maximum concentration is observed (tmax).

    Time frame: Day 1: pre-dose and t= 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr; Day 2 = 24 hr; Day 7

  4. To measure the pharmacokinetics (PK) of PVT201 in plasma following a single IV dose in healthy participants and in PBC/PSC patients.

    Pharmacokinetic parameters to be evaluated include (but are not limited to) apparent terminal elimination half-life (t1/2).

    Time frame: Day 1: pre-dose and t= 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr; Day 2 = 24 hr; Day 7

  5. To measure the pharmacokinetics (PK) of PVT201 in plasma following a single IV dose in healthy participants and in PBC/PSC patients.

    Pharmacokinetic parameters to be evaluated include (but are not limited to) total apparent body clearance (CL).

    Time frame: Day 1: pre-dose and t= 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr; Day 2 = 24 hr; Day 7

  6. To measure the pharmacokinetics (PK) of PVT201 in plasma following a single IV dose in healthy participants and in PBC/PSC patients.

    Pharmacokinetic parameters to be evaluated include area under the concentration-time curve from 0 to infinity (AUCinf).

    Time frame: Day 1: pre-dose and t= 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr; Day 2 = 24 hr; Day 7

  7. To measure the pharmacokinetics (PK) of PVT201 in plasma following a single IV dose in healthy participants and in PBC/PSC patients.

    Pharmacokinetic parameters to be evaluated include (but are not limited to) apparent volume of distribution (Vz).

    Time frame: Day 1: pre-dose and t= 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 1 hr, 2 hr, 4 hr, 6 hr, 8 hr, 12 hr; Day 2 = 24 hr; Day 7

07

Study locations

1 site
  • CMAX Clinical Research
    Adelaide, South Australia 5000, Australia
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Apr 2025, 6 months.

Of 15 phase 1 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's 6 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2024
First posted
Jan 29, 2025
StartActual
Oct 15, 2024
Primary completionActual
Apr 23, 2025
CompletionActual
Apr 23, 2025
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06798454
Lead sponsor
Parvus Therapeutics, Inc.
Collaborators
Avance Clinical Pty Ltd.
Responsible party
Sponsor
First posted
Jan 29, 2025
Start date
Oct 15, 2024
Primary completion
Apr 23, 2025
Completion
Apr 23, 2025
Last update
Nov 24, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion